Predictors and mediators of add-on mirtazapine-induced cognitive enhancement in schizophrenia - A path model investigation

Neuropharmacology

Volumn 64, Issue , 2013, Pages 248-253

  Stenberg, Jan Henry ^a   Terevnikov, Viacheslav ^b   Joffe, Marina ^a   Tiihonen, Jari ^c,d,e   Chukhin, Evgeny ^a   Burkin, Mark ^f   Joffe, Grigori ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b Kellokoski Hospital   (Finland)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

^e NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^f PETROZAVODSK STATE UNIVERSITY   (Russian Federation)

Author keywords

Adjunctive mirtazapine; Cognitive enhancer; FGA; Path analysis; RCT; Schizophrenia

Indexed keywords

MIRTAZAPINE; NEUROLEPTIC AGENT; PLACEBO;

ARTICLE; COGNITION; CONTROLLED STUDY; DEPRESSION; DEPTH PERCEPTION; DRUG MECHANISM; HUMAN; NEGATIVE SYNDROME; PARKINSONISM; PATH ANALYSIS; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; STROOP TEST; WEIGHT GAIN;

ADRENERGIC ALPHA-2 RECEPTOR ANTAGONISTS; ADULT; ANTIPSYCHOTIC AGENTS; COGNITION; COGNITION DISORDERS; DOUBLE-BLIND METHOD; DRUG MONITORING; FEMALE; HISTAMINE ANTAGONISTS; HUMANS; MALE; MIANSERIN; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NOOTROPIC AGENTS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SPATIAL BEHAVIOR; STATISTICS AS TOPIC; VISION DISORDERS;

EID: 84866345787     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2012.06.028     Document Type: Article

References (30)

1. D. Addington, J. Addington, and E. Maticka-Tindale Assessing depression in schizophrenia: the Calgary depression scale Br. J. Psychiatry 163 1993 39 44
2. S. Akhondzadeh, N. Mohammadi, M. Noroozian, N. Karamghadiri, A. Ghoreishi, A.H. Jamshidi, and S. Forghani Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial Schizophr. Res. 107 2009 206 212
3. S.A. Anttila, and E.V. Leinonen A review of the pharmacological and clinical profile of mirtazapine CNS Drug Rev. 7 2001 249 264
4. R. Delle Chiae, M. Salviati, S. Fiorentini, and M. Biondi Add-on mirtazapine enhances effects on cognition in schizophrenic patients under stabilized treatment with clozapine Exp. Clin. Psychopharmacol. 15 2007 563 568
5. S.J. Cho, K. Yook, B. Kim, T.K. Choi, K.S. Lee, Y.W. Kim, J.E. Lee, S. Suh, K.H. Yook, and S.H. Lee Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial Prog. Neuropsychopharmacol. Biol. Psychiatry 35 2011 208 211
6. M. Dominguez, W. Viecchtbauer, C.J.P. Simons, J. van Os, and L. Krabbendam Are psychotic psychopathology and neurocognition orthogonal? A systematic review of their associations Psychol. Bull. 135 2009 157 171
7. F. Fumagalli, A. Frasca, G. Racagni, and M.A. Riva Cognitive effects of second-generation antipsychotics: current insights into neurochemical mechanisms CNS Drugs 23 2009 603 614
8. C. Galletly Recent advances in treating cognitive impairment in schizophrenia Psychopharmacology 202 2009 259 273
9. M.F. Green What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry 153 1996 321 330
10. P.D. Harvey, D. Koren, A. Reichenberg, and C.R. Bowie Negative symptoms and cognitive deficits: what is the nature of their relationship? Schizophr. Bull. 32 2006 250 258
11. R.K. Heaton, J.A. Gladsjo, B.W. Palmer, J. Kuck, T.D. Marcotte, and D.V. Jeste Stability and course of neuropsychological deficits in schizophrenia Arch. Gen. Psychiatry 58 2001 24 32
12. A.R. Jensen, and W.D. Rohwer Jr. The Stroop Color-Word test: a review Acta Psychol. (Amst.) 25 1966 36 93
13. G. Joffe, V. Terevnikov, M. Joffe, J.H. Stenberg, M. Burkin, and J. Tiihonen Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial Schizophr. Res. 108 2009 245 251
14. S. Kay, A. Fiszbein, and L. Opler The positive and negative syndrome scale (PANSS) for schizophrenia Schizophr. Bull. 13 1987 261 276
15. R.S.E. Keefe, R.M. Bilder, S.M. Davis, P.D. Harvey, B.W. Palmer, J.M. Gold, H.Y. Meltzer, M.F. Green, G. Capuano, T.S. Stroup, J.P. McEvoy, M.S. Swartz, R.A. Rosenheck, D.O. Perkins, C.E. Davis, J.K. Hsiao, J.A. Lieberman CATIE Investigators; Neurocognitive Working Group Neurocognitive effects of antipsychotic medications inpatients with chronic schizophrenia in the CATIE trial Arch. Gen. Psychiatry 64 2007 633 647
16. R.S.E. Keefe, J.A. Sweeney, H. Gu, R.M. Hamer, D.O. Perkins, J.P. McEvoy, and J.A. Lieberman Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison Am. J. Psychiatry 164 2007 1061 1071
17. J.G. Kerns, and H. Berenbaum Cognitive impairments associated with formal thought disorder in people with schizophrenia J. Abnorm. Psychol. 111 2002 211 224
18. S. Klingberg, A. Wittorf, S. Sickinger, G. Buchkremer, and G. Wiedemann Course of cognitive functioning during the stabilization phase of schizophrenia J. Psychiatr. Res. 42 2008 259 267
19. M.D. Lezak Neuropsychological Assessment third ed. 1995 Oxford University Press New York
20. L.K. Muthén, and B.O. Muthén Mplus User's Guide sixth ed. 1998-2010 Muthén & Muthén Los Angeles, CA
21. M.R. Nieuwenstein, A. Aleman, and E.H. de Haan Relationship between symptom dimensions and neurocognitive functioning in schizophrenia: a meta-analysis of WCST and CPT studies J. Psychiatr. Res. 35 2001 119 125
22. G. Simpson, and J. Angus A rating scale for extrapyramidal side effects Acta Psychiatr. Scand. 45 Suppl. 212 1970 11 12
23. T. Sumiyoshi, S. Park, K. Jayathilake, A. Roy, A. Ertugrul, and H.Y. Meltzer Effect of buspirone, a serotonin 1A partial agonist, on cognitive functioning in schizophrenia: a randomized double-blind placebo-controlled study Schizophr. Res. 95 2007 158 168
24. J.-H. Stenberg, V. Terevnikov, M. Joffe, M. Tiihonen, E. Tchoukhine, M. Burkin, and G. Joffe Effects of add-on mirtazapine on neurocognition in schizophrenia: a double-blind, randomized, placebo-controlled study Int. J. Neuropsychopharmacol. 13 2010 433 441
25. J.-H. Stenberg, V. Terevnikov, M. Joffe, J. Tiihonen, E. Tchoukhine, M. Burkin, and G. Joffe More evidence on proneurocognitive effects of add-on mirtazapine in schizophrenia Prog. Neuropsychopharmacol. Biol. Psychiatry 35 2011 1080 1086
26. A. Szöke, A. Trandafir, M.E. Dupont, A. Méary, F. Schürhoff, and M. Leboyer Longitudinal studies of cognition in schizophrenia:meta-analysis Br. J. Psychiatry 192 2008 248 257
27. V. Terevnikov, J.-H. Stenberg, M. Joffe, J. Tiihonen, M. Burkin, E. Tchoukhine, and G. Joffe More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial Hum. Psychopharmacol. Clin. Exp. 25 2010 431 438
28. V. Terevnikov, J.-H. Stenberg, J. Tiihonen, M. Joffe, M. Burkin, E. Tchoukhine, and G. Joffe Add-on mirtazapine improves depressive symptoms in schizophrenia: a double-blind randomized placebo-controlled study with an open-label extension phase Hum. Psychopharmacol. Clin. Exp. 26 2011 188 193
29. J. Ventura, G.S. Hellemann, A.D. Thames, V. Koellner, and K.H. Nuechterlein Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis Schizophr. Res. 113 2009 189 199
30. D. Wechsler Wechsler Adult Intelligence Scale - Revised 1981 The Psychological Corporation San Antonio, TX